FindTrial
Sign In

microbiome of asthmatic smokers

Study for smoking effect on airway innate immune system and microbiome of asthmatic patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002252
Enrollment
40
Registered
2017-03-07
Start date
2016-12-20
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Asthma (Any of the following criteria)? -Bronchodilator response (+): FEV1(Forced Expiratory Volume in the first second) increase >12% and 200 mL -FEV1 (forced expiratory volume 1) variation (>12% and 200 ml) with or without treatment >12% and 200 mL -Airway hyperresponsiveness (+) to methacholine or mannitol provocation

Exclusion criteria

Exclusion criteria: 1. Severe medical condition (life expectancy <3 years) and current cancer 2. Severe psychiatric diseases 3. Other active airway or pulmonary (tuberculosis etc) 4. Recent exacerbation (within 3 months) 5. =40 Pack Year smoker in order to exclude COPD 6. Usage of drugs below 1 month ?:Antibiotics, antifungal agents, antiviral repellents Steroids: oral, intravenous, intramuscular that can activate inhibit the immune system: cytokines, methotrexate, anticancer drug) 7. Food: probiotics, prebiotics>

Design outcomes

Primary

MeasureTime frame
Bacterial community analysis of airway specimens by 16S rRNA metagenomic sequencing—

Secondary

MeasureTime frame
Analysis of the immune system, microbiome analyzed subjects—

Countries

Korea, Republic of

Contacts

Public ContactJae-Woo Jung

Chung-Ang Univerisity Hospital

jaewoo1439@hanmail.net+82-2-6299-1437

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026